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Abstract
The production of fully immunologically competent humanized mice engrafted with peripheral lymphocyte populations
provides a model for in vivo testing of new vaccines, the durability of immunological memory and cancer therapies. This
approach is limited, however, by the failure to efficiently engraft human B lymphocytes in immunodeficient mice. We
hypothesized that this deficiency was due to the failure of the murine microenvironment to support human B cell survival. We
report that while the human B lymphocyte survival factor, B lymphocyte stimulator (BLyS/BAFF) enhances the survival of
human B cells ex vivo, murine BLyS has no such protective effect. Although human B cells bound both human and murine
BLyS, nuclear accumulation of NF-kB p52, an indication of the induction of a protective anti-apoptotic response, following
stimulation with human BLySwasmore robust than that induced withmurine BLyS suggesting a fundamental disparity in BLyS
receptor signaling. Efficient engraftment of both human B and T lymphocytes in NOD rag12/2 Prf12/2 immunodeficient mice
treated with recombinant human BLyS is observed after adoptive transfer of human PBL relative to PBS treated controls.
Human BLyS treated recipients had on average 40-fold higher levels of serum Ig than controls and mounted a de novo
antibody response to the thymus-independent antigens in pneumovax vaccine. The data indicate that production of fully
immunologically competent humanized mice from PBL can be markedly facilitated by providing human BLyS.
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Introduction
The development of a small animal model that reproducibly
supports human lymphocyte development and/or peripheral
lymphocyte survival and function should lead to improved
treatment strategies for human tumors, autoimmune diseases
and new vaccines. Immunodeficient mice, such as NOD-Prkdcscid,
NOD-rag12/2 Prf12/2, NOD-scid IL-2Rc2/2, Balb/c-rag12/2IL-
2Rc2/2 and H2d-rag12/2IL2Rc2/2 have been used as recipients
of human peripheral blood lymphocytes (PBL) or human
hematopoietic stem cells (HSC) (reviews [1,2]). Chimeric mice
engrafted with human HSC can support B and T cell development
and the survival of peripheral T and B cell populations [3–12],
however lymphoid development following engraftment is slow (3–
6 months) and is of varying efficiency even when the same HSC
preparation is used to engraft multiple mice.
Conceptually, the engraftment of mature human peripheral blood
lymphocytes (PBL) into immunodeficient murine recipients over-
comes the need for long reconstitution times required when using
human CD34+ cord blood derived HSC and should allow for a rapid
assessment of immune responsiveness of diverse individuals, for
example, young and aged humans. In addition, the potential to
establish primary lymphoid tumors, such as leukemias and
lymphomas, in a chimeric host would provide opportunities to
investigate the efficacy of novel therapeutic strategies tailored to
individual patients. T cell engraftment is frequently observed when
PBL are transferred into NOD rag22/2 Prf12/2 and NOD rag22/2
IL-2rc2/2 mice, whereas B cell homeostasis is abnormal. Mature B
cells persist early after PBL transfer and can produce recall and
polyclonal immunoglobulin (Ig) responses, however, these B cells are
lost within 2 weeks and this loss is accelerated if CD4+ T cells are
removed from the initial inoculum [13]. These data suggest that the
murine environment may not provide the critical growth factors and/
or signaling ligands necessary for B cell homeostasis.
Mature B cells are actively maintained in vivo by survival signals
received through the B cell antigen receptor (BCR) and a receptor
for the TNF family ligand B lymphocyte stimulator, BLyS, also
known as BAFF, TALL-1, THANK, TNFSF13B and zTNF4 [14–
17]. BLyS is a type II protein produced in both membrane-bound
and soluble forms by stromal cells, macrophages, dendritic cells
and neutrophils [18]. BLyS has two proposed mechanisms of
action; to facilitate the differentiation of short-lived immature B
cells into mature recirculating long-lived B cells, and to actively
maintain mature B cells in the periphery by facilitating their
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survival through non-canonical NF-kB mediated signals [17,19–
21]. BLyS dependent survival signals are delivered through the
BLyS receptor, BR3 (BAFF-R) that is expressed on late immature
and mature peripheral B cells [18,22–24]. Two other receptors for
BLyS are also found on B cells, TACI and BCMA, and their
expression is associated with different maturation and differenti-
ation states [18,25]. In humans, BLyS has been shown to be
critical for B cell survival, the generation of lymphoid follicles and
survival of plasmablasts formed from human memory B cells
[24,26,27]. Overexpression of BLyS has been correlated with
autoimmune diseases, such as systemic lupus erythematosus and
rheumatoid arthritis [28–30], whereas lower levels of BLyS are
associated with antibody immunodeficiency [31,32]. In addition,
some human lymphoid tumors (non-Hodgkins lymphoma and
multiple myeloma) may produce BLyS as an autocrine growth
factor promoting tumor survival [33–35].
Given the critical role of BLyS in normal B cell homeostasis, we
proposed that the failure of efficient human B cell engraftment and
survival in xenochimeras may be due to a BLyS deficiency. This
failure could be due to species differences between human and
murine BLyS that affect survival signaling. Consistent with this
view, there is a single amino acid difference between the human
and murine BLyS proteins in the portion of the molecule
recognized by the BR3 receptor [18,22,23,36].
In this report, we show human recombinant BLyS improves
human peripheral blood B cell survival in vitro whereas murine
BLyS is ineffective. Moreover, engraftment of both B and T cells is
markedly enhanced in immunodeficient NOD rag22/2 Prf12/2
mice supplemented with recombinant human BLyS. All B cell
subpopulations are maintained, follicular-like structures develop
and B cells secrete antibody and respond to challenge with
thymus-independent pneumococcal antigens. Taken together, the
data demonstrate the requirement for human BLyS for efficient
engraftment of human B cells in immunodeficient mice.
Results
Human BLyS enhances human B cell survival in vitro
To establish possible species restrictions on BLyS dependent
human B cell survival in vitro, CD19+ B cells from the PBL of
normal human donors were cultured unstimulated or with human
or murine BLyS and viability determined daily. The results from
these determinations, Figure 1, clearly demonstrate that huBLyS
enhances human B cell survival relative to either unstimulated or
muBLyS supplemented cultures. Indeed, muBLyS provides no
more survival advantage for human B cells than is seen in
unstimulated cultures. Increasing the dose of muBLyS to 200 or
500 ng/ml did not improve human B cell survival (data not
shown). Donor 1 was assayed on two separate occasions, 8 months
apart, with similar results as indicated by the error bars in the
graph. Statistical analysis of pooled data from 6 donors
demonstrated the species dependence of BLyS mediated human
B cell survival (at day 4 of culture: huBLyS vs. muBLyS,
p = 0.0041; huBLyS vs unstimulated, p = 0.0014; muBLyS vs.
unstimulated, p = ns). The species dependence of BLyS mediated
human B cell survival was not observed for murine B cells,
Figure 1B; both human and murine BLyS were equally effective at
supporting murine B cell survival.
To determine if huBLyS conferred a selective survival
advantage to a particular subpopulation of PBL derived human
B cells, input populations and cells remaining after 4 days of
culture were compared by FACS using antibodies to CD19 (all B
cells), CD27 (memory B), kappa and lambda light chains, CD10
(immature B), and CD38 (immature and plasma cells). Immature
B cells (CD10+, CD272, CD38+) represented 1–3% of input B
cells from the various donors (our data and [37,38]) and were
undectable on day 4 analysis under all culture conditions. No
other significant change in the character of the surviving B cell
population relative to the input population as assessed by these
markers was observed, Figure 2 data shown from CD19 and
CD27 analysis.
Figure 1. In vitro survival of CD19+ human B cells with human
or murine BLyS. CD19+ B cells were purified from PBL by negative
selection using RosetteSep kit and ficoll hypaque centrifugation. B cells
were cultured for 4 days with 100 ng/ml of human or murine BLyS,
cultures were resupplemented with BLyS on day 2. Viability was
determined daily using cell counting with trypan blue and is
represented as percentage of input cell number surviving. Donor 1
data is the average of 2 separate B cell preparations; donors 2–6
represent a single cell preparation. Statistical analysis for significance
after 4 days in culture; huBLyS vs. muBLyS, p = 0.0041; huBLyS vs
unstimulated, p = 0.0014; muBLyS vs. unstimulate, p = ns.
doi:10.1371/journal.pone.0003192.g001
Human B Cell Survival in Mice
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muBLyS binds to human B cells but does not mobilize
NF-kB p52 as effectively as huBLyS
Murine BLyS has been shown to bind to human BLyS receptors
[39,40]. When assayed by FACS, we find that human B cells bind
both hu and mu BLyS, tested at the optimal concentration used in
our survival assays (100 ng) (Figure 3A) and also at lower
concentrations (1 and 10 ng, data not shown). These studies did
not determine which of the BLyS receptors were occupied. BLyS
signaling induces both the canonical (NF-kB1) and non-canonical
(NF-kB2) pathways; activation of the non-canonical NF-kB2
pathway is important for B cell survival [18,19,41–43]. Studies
using murine B cells have demonstrated that nuclear localization
of NF-kB p52 is sustained for at least 48–72 hours following BLyS
stimulation (laboratory observations; [18,19,44]). Our in vitro
survival data (Figure 1) shows that by 48 hours human B cell
survival in cultures supplemented with muBLyS is significantly
lower (p = 0.008) than cultures supplemented with huBLyS,
accordingly, we choose this time point to initially examine
differences in nuclear localization of NF-kB p52. Western analysis
of nuclear extracts prepared from cells after 48 hours of culture
demonstrates that nuclear accumulation of NF-kB p52 in B cells
stimulated with huBLyS was 3-fold higher than in B cells cultured
with muBLyS and 7-fold higher than unstimulated B cells
(Figure 3B, representative example). An analysis of p52 nuclear
localization in three separate B cell preparations showed huBLyS
induced on averaged 7.161.6 fold increase over unstimulated B
cells verses an average 2.460.9 fold increase with muBLyS. While,
muBLyS stimulation does result in higher nuclear accumulation of
p52 compared to unstimulated B cells, this is insufficient to support
in vitro B cell survival.
To further investigate the notion that the amount of nuclear
NF-kB p52 correlated with B cell survival, we cultured murine B
cells with varying concentrations of huBLyS and assessed cell
survival and p52 nuclear localization. We found the survival of
murine B cells cultured with 1 ng/ml of huBLyS was similar to
that observed in unstimulated cultures (figure S1A). In contrast,
both 10 and 100 ng/ml of huBLyS supported murine B cell
survival (figure 1 and figure S1A). After 48 hours of culture,
nuclear extracts were made from all cultures, western blotted for
NF-kB p52 and quantified. We observe that, similar to human B
cells, murine B cells cultured with a sub-optimal huBLyS
concentration mobilize low levels of p52 to the nucleus
(supplemental figure 1B). It is noteworthy that the amount of
nuclear p52 induced by the non-protective dose of huBLyS is
similar to that seen with human cells cultured with 100 ng of
muBLyS. Taken together, the data show a strong correlation
between survival and the amount of p52 localized to the nucleus.
Engraftment of human B cells in immunodeficient mice
To test whether huBLyS facilitated human B cell engraftment in
immunodeficient mice, we transferred 206106 human PBL by
intrasplenic injection into NOD rag12/2Ppf2/2 mice. Recipients
were given human recombinant BLyS (10 ug/mouse/day) or PBS
i.p. for 7–14 days and sacrificed for analysis on day 21. Spleen
samples were assessed by immunohistochemical staining. Figure 4
shows representative serial sections of spleens from PBS or BLys
treated mice stained with H&E, anti-human CD45 and anti-
human CD20. In PBS treated animals, the H&E staining shows
relatively uniform reticular tissue, with few scattered CD45+ cells
and no obvious formation of typical splenic architecture;
importantly, cells staining with anti-CD20 were not readily
observed (Figure 4, A and B). In marked contrast, BLyS treated
mice showed a different morphology by H&E staining. Numerous
follicle-like collections of human lymphocytes were observed and
these stained strongly with anti-CD45 (both T and B cells) and
with anti-CD20 (B cells) antibodies (Figure 4, C–E, CD45 and
CD20). Higher magnification of the serial sections shown in
Figure 5 clearly demonstrates CD45+ cells in areas not staining
with CD20 suggesting the presence of T cells (see below). For
comparison, we estimate the extent of human B cell engraftment
by averaging the area of CD20+ staining cells within a number of
microscopic fields. Among mice treated for 14 days with human
BLyS, B cells comprise 30–50% of the spleen section areas
(Figures 4 and 5, D and E), whereas, mice receiving BLyS for only
7 days generally had smaller areas of B cell engraftment,
approximately 20–25% of the spleen sections (Figures 4 and 5,
C). We evaluated the possibility that the marked B cell
engraftment we observed was the result of an EBV-mediated
lymphoproliferative disorder, however, the B cells in BLyS treated
recipients were negative for EBV when examined by EBER-1 in
situ hybridization (data not shown). This data is consistent with
previous observations suggesting that three-fold higher numbers of
PBL or depletion of CD8+ T cells are required for EBV-mediated
lymphoproliferation in engrafted immunodeficient mice [13].
Figure 2. FACS analysis of B cell cultures. B cell populations were FACS analyzed for surface markers associated with resting B cells (CD45,
CD19), memory cells (CD27), plasma cells (CD38) and kappa and lambda light chains on the day of isolation and after 4 days of culture either
unstimulated or stimulated with human or murine BLyS. All samples were initially gated for lymphocytes by forward and side scatter. Data
representative of 4 experiments.
doi:10.1371/journal.pone.0003192.g002
Human B Cell Survival in Mice
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Whereas lymphocyte organization is revealed by immunohis-
tology, more definitive quantitation of the human lymphocyte
engraftment was assessed by flow cytometry. Spleens were divided
in half upon harvest, with one half prepared for immunohistolog-
ical analysis and the other prepared for FACS analysis by digestion
with collagenase. Human lymphocyte yields (CD45+) from PBS
treated recipients ranged between 0.27–5.86106 cells/spleen,
whereas, significantly more cells were isolated from recipients
treated with BLyS (7.7–20.26106 cells/spleen). The human B cell
yields from the BLyS treated spleens was usually higher (4.1–
9.56106 cells/spleen) than the number of input B cells (26106; 5–
10% of total PBL) used to reconstitute the mice indicating that the
engrafted cells had undergone proliferative expansion, perhaps by
homeostatic proliferation induced by lymphocyte deficiency [45–
47] or antigenic stimulation. Indeed, immunohistological staining
of splenic sections with anti-Ki67, a marker for cells that have
recently proliferated, was positive for almost all cells within the
sections in BLyS-treated recipients whereas only scattered cells
were positive in PBS-treated recipients (data not shown).
Representative samples of collagenase disrupted spleens from
separate experiments were analyzed by FACS (Figure 6) and
showed that while T cells were present in some of the PBS treated
mice (examples of positive engraftment shown with lymphocyte
yield from test spleen), few, if any, B cells were detected in the
same spleens. In contrast, both human B and T cells are readily
detected in the huBLyS treated mice.
A summary of in vivo engraftment efficiency is shown in
Table 1. Of the 16 mice treated with PBS, only 7 engrafted T cells
and one of those 7 also engrafted B cells, overall 43% of the mice
contained human lymphocytes. The PBS treated mice that were
Figure 4. Immunohistology of in vivo PBL engraftment in NOD
rag22/2 Prf12/2 mice. On day of sacrifice, day 21 post PBL transfer,
spleens were harvested and fixed for immunohistological analysis of B
and T cell engraftment. Sections were visualized and photographed
using a nikon microscope. All images were taken at 206magnification.
Rows A and B are PBS treated mice; C from mice treated 7 days with
BLyS and, D and E from mice treated for 14 days with BLyS (10 ug/
mouse/day). All mice were untreated days 14–21 prior to sacrifice. Serial
sections were stained with hemotoxylin and eosin, anti-human CD45 or
anti-human CD20. Data is representative of 6 experiments.
doi:10.1371/journal.pone.0003192.g004
Figure 3. Nuclear localization of NF-kB p52. Purified CD19+
human B cells were A.) incubated with 100 ng/106 cells of FLAG-huBLyS
or FLAG-muBLyS followed by biotinylated anti-FLAG and strep-avidin
PerCP on the day of isolation prior to FACS analysis. Control stain with
anti-FLAG and PerCP (dash/dot line); huBLyS (solid line) and muBLyS
(dark dashed line) B.) B cells were cultured unstimulated or with 100 ng/
ml of human or murine BLyS for 48 hours. Cells were harvested, nuclear
extracts prepared and Western blots prepared following protein
separation on a 4–12% SDS gel. Blots were probed with anti-p52
antibody then stripped and reprobed with anti-TATAbpa antibody.
Blots were developed by ECL. Data representative of 3 separate expts.
doi:10.1371/journal.pone.0003192.g003
Human B Cell Survival in Mice
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positive for human T or B cells had far fewer engrafted cells as
determined by the sparse immunohistological staining; and
reduced viable spleen cell yields. In comparison, 88% of the
BLyS treated mice showed engraftment of both B and T cells with
significantly higher numbers of donor splenocytes being isolated
from these mice.
Human BLyS is required for maintenance of the
engrafted B cells
Human BLyS is required to initiate engraftment of B cells from
human PBL in NOD rag12/2Ppf2/2 mice and we noted that mice
receiving BLyS for only 7 days had lower amounts of B cells
compared with mice receiving 14 days of treatment (20–25% vs
30–60%, determined by comparison of overall CD20 staining of
histology sections, Table 2). To examine whether human B cells
required the continued presence of huBLyS for in vivo survival as
we would predict from murine B cell studies, a group of animals
was treated for 7 days with huBLyS followed by injections of the
soluble BLyS decoy receptor TACI-Ig protein (10 ug/mouse/day)
for the next 7 days. TACI-Ig will bind both human and murine
BLyS creating a BLyS deficient environment. Mice were sacrificed
at day 21 and immunohistological analysis carried out on the
spleens. We found that B cells were reduced when BLyS was
withdrawn during PBS injections (about 2-fold lower) and were
further reduced when mice received the BLyS decoy receptor (10-
fold lower, Table 2, summary of histology results). Immunohisto-
logical analysis showed that T cells were still present (data not
shown). Thus, maintenance of peripheral human B cell popula-
tions in reconstituted immunodeficient mice still require huBLyS.
In vivo antibody production
To determine if the B cells in recipient mice were functional, we
assessed human antibody production in mice treated with PBS or
huBLyS for 14 days. NOD rag12/2Ppf2/2 mouse serum had
undetectable levels of antibody. PBS treated recipients averaged
5 ug/ml of IgM and 60 ug/ml of IgG suggesting some early
activation of transferred B cells prior to their loss from the animals.
Recipients treated 14 days with BLyS had 40 fold more IgM,
average 200 ug/ml, and 10 fold more IgG, 570 ug/ml consistent
with the levels of B cell engraftment found (Table 3). To determine
if antibody production was sensitive to BLyS depletion, mice were
treated for 7 days with BLyS or 7 days with BLyS and then 7 days
of TACI-Ig decoy receptor. Mice treated with TACI-Ig had
approximately 8-fold lower amounts of IgM, 28 ug/ml, and 2-fold
lower IgG compared to recipients receiving 14 days of BLyS
treatment; consistent with TACI-Ig depletion of B cells and with
the different half-lives of the antibody classes.
To assess the antigen responsiveness of transferred B cells, PBL
recipients were immunized with pneumovax23, to test whether
engrafted B cells could produce a de novo antibody response to a
thymus-independent type 2 antigen. Recipient mice were
vaccinated on the day of PBL transfer and serum collected at
day 21 and analyzed with a serotype specific ELISA. Shown in
Table 4 is the data for Streptococcus pneumoniae serotype 14, one
of the 23 pneumococcal polysaccharide strains in the vaccine.
Serum from PBL engrafted mice receiving PBS, huBLyS or PBS
plus vaccine had a similar low quantity of anti-polysaccharide
antibody, ranged between 0.7–1.4 ng/ml for IgM and 2.4–
3.3 ng/ml for IgG. In striking contrast, recipients of huBLyS
and vaccine averaged 10-fold higher amounts, 9 ng/ml IgM and
45 ng/ml IgG, of serotype 14 specific antibody. Similar levels of
IgG and IgM were observed for pneumococcal serotype 4 (data
not shown). These data demonstrate that the human B cells in PBL
recipients can respond de novo to challenge with T cell
independent antigens.
Discussion
These experiments demonstrate the requirement for human
BLyS to efficiently reconstitute human B cells in NOD rag12/2
Ppf2/2 immunodeficient mice. A species specific BLyS restriction
is demonstrated for human B cells in culture and for B cells
transferred to murine hosts. The NOD rag12/2Ppf2/2 environ-
ment is not BLyS deficient, per se, as these mice readily support
the engraftment of murine B cells. Species specificity in the action
of survival and growth promoting cytokines is not novel to
members of the TNF family; IL-2, IL-5, IL-6, and gamma
interferon have all demonstrated species restrictions [18,48–52].
Moreover, amino acid differences between murine and human
BLyS in the BR3 receptor binding region and/or differences in the
Figure 5. Immunohistology. Higher magnification images (1006) of
portions of the sections shown in figure 3. Estimates of percentages of
B cell engraftment are done at this magnification by comparing the
percentage of the splenic section staining with anti-CD20.
doi:10.1371/journal.pone.0003192.g005
Human B Cell Survival in Mice
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BLyS binding region of the BR3 receptor are known to have
marked effects on survival signaling for human B cells
[18,22,23,53]. While we favor the notion that the basis for species
restriction is in the interaction between BLyS and BR3, human B
and T cells also express the TACI receptor for BLyS and
differences in huBLyS and muBLyS binding to and signaling
through TACI may also contribute to our results.
In vitro, human BLyS supported significantly better human B
cell survival than did murine BLyS, which was indistinguishable
from unsupplemented cultures. In contrast, human and murine
BLyS were equally effective at promoting the in vitro survival of
murine B cells. Concurrent with the survival effect, BLyS
stimulation leads to a prolonged induction of NF-kB p100
processing and nuclear localization of NF-kB p52 (laboratory
observations and [19,44]). While freshly isolated human B cells
Table 1. Summary of in vivo engraftment data.
group #mice CD45 (T+B)* CD20 (B)* %positive
PBS 16 7 1 43
BLyS 33 29 29 88
Data from immunohistological analysis of splenic sections from NOD rag12/2
Prf12/2mice receiving 206106 PBL and then given 10 ug/mouse/day of huBLyS
or PBS controls for 12–14 days and then sacrificed on day 21 post cell transfer.
Sections were rated as positive if any CD45 or CD20 staining was observed at
all.
*postitve sections as determined by immunohistological staining.
doi:10.1371/journal.pone.0003192.t001
Table 2. BLyS decoy receptor decreases B cell engraftment in
NOD rag12/2 Prf12/2 mice.
group CD45 CD20 % B
BLyS 14 days + + 30–50
BLyS 7 daysRPBS 7 days + + 20–25
BLyS 7 daysRTACI 7 days + +/2 ,5–10
In two experiments, NOD rag12/2 Prf12/2 mice were given 206106 PBL were
injected i.p. for 7 days with 10 ug/day/mouse of huBLyS, then divided into 3
groups of 3 mice each, the 3 groups received either PBS, 10 ug/day/mouse of
huBLyS or 10 ug/day/mouse of TACI-Ig for 7 more days. Animals were sacrificed
on day 21 and spleens analyzed by immunohistochemistry. Percentage of B cell
engraftment was determined by analysis of the percentage of splenic sections
staining with anti-CD20 and by FACS analysis of collagenase disrupted spleen
samples.
doi:10.1371/journal.pone.0003192.t002
Figure 6. FACS analysis of collagenase disrupted engrafted spleens. One half of engrafted spleens were collagenase digested and then
stained with anti-human CD45, CD20 and CD3 antibodies and analyzed by FACS. All samples were gated on live lymphocytes by forward and side
scatter and then on CD45 positive cells. Data representative of 3 experiments. Total lymphocyte number= spleen cell count6percentage of CD45+
cells.
doi:10.1371/journal.pone.0003192.g006
Table 3. Human serum Ig.
group
human IgM
(ug/ml)
human IgG
(ug/ml)
NOD rag2/2Pfp2/2 (n = 3) ND* ND
PBS (n = 6) 5.263.8 60.2638.1
BLyS 7 days (n = 3) 26.164.6 438.7689.9
BLyS 7 daysRTACI 7 days (n = 3) 28.462.1 310.7635.3
BLyS 14 days (n = 6) 200644.5 572.5622.7
Serum was collected at the time of sacrifice, day 21, and analyzed for human
IgM and IgG synthesis from PBL engrafted mice treated for 14 days with PBS or
BLyS, 7 days with BLyS, or 7 days with BLyS followed by 7 days of TACI-Ig. Data
is representative of 3 experiments.
*ND, none detected, below the 3 ng sensitivity of the assays.
doi:10.1371/journal.pone.0003192.t003
Table 4. Induction of a thymus-independent immune
response in human PBL engrafted NOD rag12/2 Prf12/2 mice.
Antibody Group serotype 14 IgM serotype 14 IgG
ng/ml ng/ml
PBS (n = 6) 0.6860.16 2.8860.35
PBS+pneumovax (n = 4) 0.7260.12 2.4260.23
huBLyS (n = 6) 1.3560.41 3.3060.51
huBLyS+pneumovax (n = 6) 9.0263.77 45.6620.4
PBL recipient mice were immunized with 20 ul/mouse pneumovax23 s.c. on the
day of cell transfer. Serum was harvested on the day of sacrifice and assayed by
ELISA for Streptococcus pneumoniae serotype 14 specific antibodies. Data
representative of two experiments.
doi:10.1371/journal.pone.0003192.t004
Human B Cell Survival in Mice
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bind FLAG-tagged murine BLyS as efficiently as human BLyS,
p52 nuclear localization in human B cells induced by human BLyS
was more robust than that induced by murine BLyS. This shows a
dissociation between BLyS binding and survival signaling which
may be the result of a species difference in the binding
requirement for activation of BR3/TACI receptors on human B
cells. It is noteworthy that in titration of human BLyS on murine B
cells diminished B cell survival was correlated directly with the
extent of p52 nuclear localization (supplemental figure 1). Our
laboratory has recently defined the survival pathways induced by
BLyS in murine B cells [54] and further experiments are in
progress to define these pathways in human B cells.
Engraftment of human B cells is efficient in huBLyS treated
NOD rag12/2Ppf2/2 recipients. Human BLyS is continually
required to maintain the B cells over the 3 week period used in
these studies since treatment with a BLyS decoy receptor, TACI-
Ig, which depletes both human and murine BLyS from the
animals, resulted in loss of B cells as assessed by immunohisto-
logical analysis and resulted in lower serum IgM and IgG
compared with mice treated for 14 days with BLyS. Our
engraftment data using huBLyS supplementation contrasts from
that observed in other PBL xenochimera models where few, if any,
human B cells are observed after cell transfer and those B cells do
not survive beyond one week [10,13,55–60].
The B cells are functional as we find significantly higher
amounts of human IgM and IgG in chimeras receiving huBLyS
compared with PBS treated controls. Human Ig production could
result from the homeostatic activation of naı¨ve or memory B cells.
Homeostatic B cell proliferation is seen when murine B cells are
transferred into B cell deficient environments [45,61,62], however
this mechanism has not been evaluate in xenochimeras. It is also
possible that activation by xenoantigens can contribute to B cell
activation and serum Ig. The antigen responsiveness of engrafted
human B cells and the ability to induce a de novo immune
response is demonstrated by the production of anti-pneumococcal
antibodies following immunization with the thymus-independent
antigens in pneumovax23. There was a 10–20 fold increase,
respectively in IgM and IgG, in pneumococcal antibodies in BLyS
treated recipients compared to BLyS treated and unimmunized
and PBS treated immunized controls. This xenochimera model
with enhanced B cell engraftment provides a unique opportunity
to test vaccine responses using PBL samples from a variety of
individuals, including neonates and the aged who frequently
exhibit weak immune responsiveness.
Immunohistological analysis of recipient mice receiving only
PBS revealed only scattered human T cells but these cells were
readily identified by FACS analysis of collagenase digested spleens.
It was noted, however, that there was a marked improvement of T
cell engraftment with human BLyS supplementation. Both T and
B cell yields from BLyS treated recipients was much higher than
that observed with PBS treated recipients. Recent publications
demonstrate that BLyS can act as a co-stimulator for T cells acting
through BR3 and/or TACI [63–66]. T cells, like B cells, will
under go homeostatic proliferation when introduced to a T cell
deficient environment [45,46,67–69]. This proliferation causes
induction of early activation markers, including expression of BR3
mRNA and protein on T cells [63]. Human T cells may also
undergo activation to xenoantigens in the murine environment,
again upregulating the BLyS receptor. In this regard, it is also
possible that the human B cells themselves can present antigen to
the T cells, thereby facilitating T cell expansion and survival.
TACI-BLyS signaling in B cell-dendritic cell interactions have
been shown to increase the expansion of antigen responsive CD8+
T cells [70] whereas BR3-BLyS costimulates CD4+ T cell
alloresponses [66]. We did note that use of the TACI decoy
receptor in vivo resulted in loss of both B and T cells, although B
cells were affected to a greater degree. Taken together, these data
suggest that human T cell engraftment may also be enhanced
directly or indirectly by human BLyS treatment. Further studies
using purified human T cells and human BLyS supplementation
should address whether human BLyS acts directly on T cells to
facilitate engraftment.
Since huBLyS enhances engraftment of both B and T cells, we
considered the possibility that prolonged exposure to huBLyS may
increase the rate of graft verses host disease (GVH) in the PBL
recipient mice. No GVH was seen by observation or histological
analysis at the 3 week time points assessed in these experiments even
in recipients with the robust B and T cell engraftment, however,
other investigators have found evidence of GVH by 4–6 weeks post-
PBL engraftment in a variety of immunodeficient murine hosts
[1,71]. Regulatory T cells have recently been shown to express
BLyS receptors and it is possible that huBLyS treated animals
engraft sufficient regulatory cells to delay or prevent GVH [63,65].
Our data suggest recombinant human BLyS has a significant
enhancing effect on the engraftment of both T and B cell
populations in PBL.
Materials and Methods
Human lymphocytes
Human blood was obtained from healthy volunteers and blood
donors under signed consent in accordance with the Declaration
of Helsinki and approval from the Institutional Review Board of
the University of Massachusetts Medical School. Total human
peripheral blood mononuclear cells (PBL) were purified by Ficoll
gradient separation, quantified and viability assessed by trypan
blue exclusion. Human CD19+ B cells were purified from PBL by
negative selection using RosetteSep (StemCell Technologies,
Vancouver BC, Canada).
Murine lymphocytes
Murine B cells were prepared by anti-thy1.2 and complement
treatment of splenocytes followed by purification of resting B cells
using a step percoll gradient harvesting cells at the 60–70%
interface [72].
Mice
NOD/Cg-Rag1tm1MomPpftm1Sclz/SzJ (abbreviated NOD rag12/2
Ppf2/2, stock # 004848) and C57BL/6 mice were obtained from
Jackson Laboratories and NCI, respectively. Mice were housed at
the University of Massachusetts Medical School under specific
pathogen free conditions in accordance with federal and
institutional IACUC guidelines. Immunodeficient mice received
acidified (HCl; pH 2.8–3.2) water containing trimethoprim-
sulfamethoxazole (Goldline Laboratories, Ft. Lauderdale, FL) ad
librium for 7 consecutive days every other week.
BLyS
Two sources of human BLyS were used in these experiments.
Purified recombinant human BLyS (huBLyS, Human Genome
Sciences, Rockville, MD 20850) or recombinant human FLAG-
tagged BLyS (FL-BLyS) purified in our laboratory from transfect-
ed CHO cell supernant (cell line generously provided by Dr.
Randolph Noelle, Dartmouth Univ. Lebanon, NH). Briefly, stably
transfected CHO cells were grown in DMEM (7%FCS, 2 mM
glutamine, 16 MEM non-essential amino acids, 10 units/ml
penicillin and 10 ug/ml streptomycin) and supernatants collected.
Supernatants were dialyzed against 50 mMTris pH 8.0, 50 mM
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NaCl, 0.02% sodium azide prior to running over an anti-FLAG
M2 agarose column (Sigma-Aldrich Biochemicals). FL-BLyS was
eluted with 0.1 M glycine HCl pH 3.0 and dialyzed against PBS,
incubated with polymyxin B-agarose beads (Sigma-Aldrich, 1 ml
of 50% suspension per 15 mls) for I hour, sterile filtered and
quantitated by spectrophotometry (1 OD280 = 1.15 mg/ml). Purity
was assessed by SDS-PAGE and Western blot. All human BLyS
preparations tested negative for endotoxin and mycoplasma. Both
huBLyS and FL-BLyS performed equivalently and were used
interchangeably in these experiments. FLAG-tagged murine BLyS
(muBLyS) (#522-052-C010) was obtained from Alexis biochem-
icals (Axxora, San Diego, CA 92121).
Cell culture
Purified CD19+ B cells (94–98% pure by FACS analysis) were
cultured at 56106 cells per ml in RPMI 1640 - complete media
(CM: 10% FCS, 2 mM glutamine, 16 non-essential DMEM
amino acids, 10 units/ml penicilin, 1 ug/ml streptomycin,
561025 M 2-mercaptoethanol) alone or in the presence of
100 ng/ml of human or murine BLyS for 4 days. Preliminary
experiments established the dose of BLyS sufficient for optimal cell
survival: 1, 10, 100, 250 and 500 ng/ml were tested and no
significant differences on cell survival were found at doses of
10 ng/ml or greater. BLyS was readded to the cultures on day 2.
Cell survival was determined by counting daily using trypan blue
exclusion for viability. Input populations and cells remaining after
4 days of culture were stained for human CD19, CD27, CD38,
CD10, kappa and lambda light chains and analyzed by FACS.
In vivo engraftment
In preparation for engraftment NOD rag12/2Ppf2/2 received a
single i.p. injection of 1.0 mg of TMb1 (anti-CD122) monoclonal
antibody for depletion of NK cells and 10 ug of purified human
recombinant BLyS (huBLyS). Recipients received 206106 PBL by
intrasplenic injection followed by daily i.p. injection of 10 ug huBLyS
or endotoxin free PBS for 7–14 days. Spleens were harvested 14–21
days post PBL transfer and processed for immunohistochemisry. In
some expts, spleens were bisected and each half processed for either
immunohistochemistry or FACS analysis.
Decoy receptor
To deplete BLyS in vivo, groups of 3 mice that had previously
received huBLyS for 7 days were given soluble TACI-Ig (10 ug
i.p./mouse/day, Human Genome Sciences) for 7 subsequent days.
Antibodies
Sources of anti-human antibodies used for FACS staining.
Caltag: CD3-FITC, CD45-APC, CD45-PE, CD20-APC, CD19-
APC, CD19-PE, IgD-FITC, CD38-PE; ebioscience: CD27-FITC,
CD138-FITC and PE, CD10-biotin, kappa-biotin, lambda-biotin:
BD Pharmingen: streptavidin-PerCP, IgM-APC, and CD45-
PECy5.5. For immunohistochemistry BD Pharmingen: CD45,
CD3, CD20, Ki67, and EBNA1.
Immunohistochemistry
At sacrifice, spleens were fixed in 10% neutral buffered
formalin, embedded in paraffin, and 5 um tissue sections were
cut. Immunohistochemical staining was performed with human
specific mABs (BD Pharmingen, San Diego, CA). Prior to staining
sections were incubated in 0.1 M citrate buffer (pH 6.0) for
15 mins and then stained on a Dako (Carpinteria, CA) automated
immunostainer using the EnVision (Dako) staining procedure. The
sections were incubated with the EnVision plus Dual Link reagent
(a polymer conjugated with goat anti-rabbit Ig or goat anti-mouse
Ig and horseradish peroxidase) for 30 min. The sections were
washed and reacted with 3-diaminobenzidine and hydrogen
peroxide and counterstained with hemotoxylin for visualization
by light microscopy.
Flow cytometry
For in vitro experiments, purified PBL B cells were tested for
purity and subpopulations characterized after initial isolation and 4
days of culture using CD45, CD19, CD20, CD27 and CD38
antibodies conjugated with APC, Fitc, PE or PerCp, described
below. BLyS binding was determined by incubating 106 purified B
cells with 100 ng of murine or human FL-BLyS, followed by
biotinylated anti-FLAG antibody (#F9291, SigmaAldrich) and
strept-avidin PerCP (BD). FACS analysis of human lymphocyte
engrafted mice was performed as follows: half of each recipient
spleen was minced and incubated in 0.5ml HBSS containing
2.4 mg/ml collagenase XI (SigmaAldrich), 1 mg/ml DNAse I and
2% FCS for one hour at 37uC in a shaking water bath. Cell
suspensions were then washed twice with CM, resuspended in 1 ml
CM and incubated for one hour at 37uC in a CO2 incubator prior
to FACS staining. Single cell suspensions were washed into FACS
buffer (PBS, 3%FCS, 0.02% sodium azide) and106 cells in 100 ul
kept on ice for staining. Nonspecific staining was blocked by
incubating cells with rabbit and mouse IgG (3ug) or 10 ul of
C57BL/6 mouse serum for 10 mins on ice prior to adding
fluorchrome-labeled antibodies. Cells were stained for 30–45 mins,
washed and fixed with 2% paraformaldehyde prior to analysis.
Engrafted cell numbers were determined from total cell counts
isolated by collagenase multiplied by 2 (half of each spleen digested)
and by the percentage of human CD45+ cells. Samples were
analyzed using BD FACScalibur or FACSVantage machines and
data analyzed using FlowJo software (Tree Star Inc., Ashland, OR).
Western blotting
Purified CD19+ B cells were cultured unstimulated or with
100 ng/ml of mu FL-BLyS or hu FL-BLyS for 48 hours. Cells
were harvested and nuclear and cytoplasmic extracts prepared as
described [73]. Protein content was determined using Commassie
protein assay reagent (Pierce Biotechnology, Rockland, IL)
Samples were run on 4–12% NuPAGE MOPS gels (Invitrogen)
and transferred to nitrocellulose membrane overnight. Mem-
branes were blocked with 5% BSA, PBS, 0.2% Tween-20 buffer,
anti-p100/p52 antibody (#4882, Cell Signaling Technology,
Danvers, MA) or TATA binding protien (#AB818, Abcam,
Cambridge Science Park, UK) as nuclear loading control added
and incubated overnight at 4uC. Filters were washed with
PBS+0.2%Tween-20, incubated with goat anti-rabbit HRP (Cell
Signaling Technology), washed and developed using Amersham
ECL plus detection system. Quantitation of signal was performed
using a Molecular Dynamics Densitometer and BioRad Multi-
analyst software.
Determination of serum Ig
To assess polyclonal Ig production, sera were collected from cell
recipients at the time of sacrifice and assayed for human Ig by
ELISA. ELISA plates were coated overnight with 3 ug/ml F(ab9)2
goat anti-human IgG or IgM (Jackson Immunologicals) in PBS,
100 ul/well. Plates were washed with PBS, blocked for one hour
with 0.5% BSA in PBS and serum dilutions added and incubated
1–2 hours. After washing, biotinylated anti-human kappa and/or
lambda antibodies were added followed by washing and addition
of streptavidin-HRP. The assay was developed with tetramethyl-
benzidine dihydrochloride (Sigma-Aldrich), stopped with sulfuric
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acid and read at 450 nm. Limits of detection were 3 ng/ml for
IgM and 2 ng/ml for IgG.
Immunizations
In two experiments, engrafted mice were immunized with
pneumovax 23 (Merck, Whitehouse Station, NJ), 20 ul/mouse s.c.
(containing 1 ug of each of 23 pneumococcal serotypes) on the day
of cell transfer.
Pneumovax ELISA
Immune responses to pneumovax23 were examined for 2 of the
23 pneumococcal serotypes, 4 and 14 (Danish strain designation)
in the vaccine. ELISA analysis was performed according to WHO
protocol (www.vaccine.uab.edu). Briefly, polystyrene ELISA plates
were coated with 100 ul of 1 ug/ml serotype specific polysaccha-
rides (type 4, ATCC #18-X and type 14, ATCC #23-X) for
5 hours at 37uC. Control human serum (89SF-2, US reference
standard generously provided by Dr. Carl Frasch, CBER/FDA,
Rockville, MD) with known concentrations of IgG and IgM to
each serotype was used as a standard. Control serum and serial
dilutions of unknowns were added to the plates, incubated
overnight at room temperature. Plates were washed and incubated
with anti-human IgG biotin or anti-human IgM biotin (#2040-08
and #2020-08, respectively, Southern Biotech, Birmingham, AL)
for 2 hours, washed and strep-avidin-alkaline phosphatase (South-
ern Biotech) added for 1 hour. After washing the assay was
developed with 1 mg/ml p-nitrophenyl phosphate in diethanol-
amine substrate for 2 hours, fixed with 3 M NaOH and read at
OD 405 nm and 690 nm. Concentration determined as OD405-
OD690 and read off the standard curve.
Supporting Information
Figure S1
Found at: doi:10.1371/journal.pone.0003192.s001 (0.15 MB TIF)
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